CD8A and cancer: It has also been found that GZMK plays an anti-cancer role in CM, activating immune signaling pathways and responses in low-risk patients, especially when CD8+ T cells are highly expressed, resulting in greater benefits from anti-PD-1 therapy (Wu et al. 2021b).